University of California, Irvine
Division of University of California
Latest From University of California, Irvine
With new branded immunotherapy-based double- or triple-drug combinations on the way, there is greater scrutiny of costs and efficiency.
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
Canaan raised $800m for tech and health care investments. Also, six companies closed VC rounds, CARB-X backed more antibiotics, CIRM funded BrainStorm and Sarepta led recent offerings.
A handheld biosensor in development by PhageTech Inc. is designed to detect the presence of several biomarkers associated with the recurrence of bladder cancer from a small urine sample, without the need for expensive and time-consuming lab-based tests. The device could also monitor treatment.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.